Our client, a leading biotech innovator committed to developing revolutionary personalized therapies for dementia and Alzheimer’s disease patients, relies heavily on positive outcomes from its clinical trials. Yet, identifying appropriate patients with the right gene mutation for these trials can be a challenge. When trial sites failed to identify enough patients for a phase 3 …
Patient populations affected with orphan diseases are rare and patient identification can be challenging and time-consuming. Our pharmaceutical client, while anticipating likely FDA approval for its new gene therapy, faced significant challenges identifying affected patients and encouraging the adoption of genetic testing into community physician practices. Learn how the InformedACCESSTM solution we deployed with our client resulted …
Case Study: Post-Market Success for a New Gene Therapy Read More »
Payment Integrity Edits Identify $26.5M in Inappropriate Genetic Testing Payments Driven by the rapid and ongoing increase in the number of genetic tests available on the market, genetic testing spending is projected to increase from $13B in 2020 to $29B by 2026. The growth and complexity of these tests create clinical and payment appropriateness challenges. …
